Treatment of heart failure with preserved ejection fraction

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Approximately half of all patients with chronic heart failure (HF) have a preserved ejection fraction (HFpEF) (1). Morbidity and mortality are high, and similar to patients with systolic heart failure (SHF) (2). In contrast to the wealth of data available from large-scale clinical trials in SHF, there is little evidence to guide treatment decisions in HFpEF (3). This relates to an incomplete pathophysiologic understanding, the lack of randomized trial data currently available, and the relatively equivocal findings noted in the studies published to date. Treatments with dramatic benefits in SHF have had less impressive effects in HFpEF (4,5). Fundamental disparities in ventriculoarterial mechanical properties in HFpEF produce different clinical responses to common drugs such as vasodilators and diuretics, and novel agents more specifically targeting these abnormalities may ultimately prove more effective (6). In this chapter, we shall first examine the pathophysiology of HFpEF to better predict and understand responses to various treatments. Data regarding specific medications, most of them commonly used in SHF, will be reviewed. Finally, future therapies that are or will soon be tested in clinical trials will be explored.

Original languageEnglish (US)
Title of host publicationHeart Failure, Second Edition
PublisherCRC Press
Pages377-387
Number of pages11
ISBN (Electronic)9781420077018
ISBN (Print)9781420076998
StatePublished - Jan 1 2012

Fingerprint

Systolic Heart Failure
Treatment Failure
Heart Failure
Clinical Trials
Therapeutics
Vasodilator Agents
Diuretics
Morbidity
Mortality
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Borlaug, B. A. (2012). Treatment of heart failure with preserved ejection fraction. In Heart Failure, Second Edition (pp. 377-387). CRC Press.

Treatment of heart failure with preserved ejection fraction. / Borlaug, Barry A.

Heart Failure, Second Edition. CRC Press, 2012. p. 377-387.

Research output: Chapter in Book/Report/Conference proceedingChapter

Borlaug, BA 2012, Treatment of heart failure with preserved ejection fraction. in Heart Failure, Second Edition. CRC Press, pp. 377-387.
Borlaug BA. Treatment of heart failure with preserved ejection fraction. In Heart Failure, Second Edition. CRC Press. 2012. p. 377-387
Borlaug, Barry A. / Treatment of heart failure with preserved ejection fraction. Heart Failure, Second Edition. CRC Press, 2012. pp. 377-387
@inbook{00e380e8b0c745eea1796dd67e24a2d3,
title = "Treatment of heart failure with preserved ejection fraction",
abstract = "Approximately half of all patients with chronic heart failure (HF) have a preserved ejection fraction (HFpEF) (1). Morbidity and mortality are high, and similar to patients with systolic heart failure (SHF) (2). In contrast to the wealth of data available from large-scale clinical trials in SHF, there is little evidence to guide treatment decisions in HFpEF (3). This relates to an incomplete pathophysiologic understanding, the lack of randomized trial data currently available, and the relatively equivocal findings noted in the studies published to date. Treatments with dramatic benefits in SHF have had less impressive effects in HFpEF (4,5). Fundamental disparities in ventriculoarterial mechanical properties in HFpEF produce different clinical responses to common drugs such as vasodilators and diuretics, and novel agents more specifically targeting these abnormalities may ultimately prove more effective (6). In this chapter, we shall first examine the pathophysiology of HFpEF to better predict and understand responses to various treatments. Data regarding specific medications, most of them commonly used in SHF, will be reviewed. Finally, future therapies that are or will soon be tested in clinical trials will be explored.",
author = "Borlaug, {Barry A}",
year = "2012",
month = "1",
day = "1",
language = "English (US)",
isbn = "9781420076998",
pages = "377--387",
booktitle = "Heart Failure, Second Edition",
publisher = "CRC Press",

}

TY - CHAP

T1 - Treatment of heart failure with preserved ejection fraction

AU - Borlaug, Barry A

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Approximately half of all patients with chronic heart failure (HF) have a preserved ejection fraction (HFpEF) (1). Morbidity and mortality are high, and similar to patients with systolic heart failure (SHF) (2). In contrast to the wealth of data available from large-scale clinical trials in SHF, there is little evidence to guide treatment decisions in HFpEF (3). This relates to an incomplete pathophysiologic understanding, the lack of randomized trial data currently available, and the relatively equivocal findings noted in the studies published to date. Treatments with dramatic benefits in SHF have had less impressive effects in HFpEF (4,5). Fundamental disparities in ventriculoarterial mechanical properties in HFpEF produce different clinical responses to common drugs such as vasodilators and diuretics, and novel agents more specifically targeting these abnormalities may ultimately prove more effective (6). In this chapter, we shall first examine the pathophysiology of HFpEF to better predict and understand responses to various treatments. Data regarding specific medications, most of them commonly used in SHF, will be reviewed. Finally, future therapies that are or will soon be tested in clinical trials will be explored.

AB - Approximately half of all patients with chronic heart failure (HF) have a preserved ejection fraction (HFpEF) (1). Morbidity and mortality are high, and similar to patients with systolic heart failure (SHF) (2). In contrast to the wealth of data available from large-scale clinical trials in SHF, there is little evidence to guide treatment decisions in HFpEF (3). This relates to an incomplete pathophysiologic understanding, the lack of randomized trial data currently available, and the relatively equivocal findings noted in the studies published to date. Treatments with dramatic benefits in SHF have had less impressive effects in HFpEF (4,5). Fundamental disparities in ventriculoarterial mechanical properties in HFpEF produce different clinical responses to common drugs such as vasodilators and diuretics, and novel agents more specifically targeting these abnormalities may ultimately prove more effective (6). In this chapter, we shall first examine the pathophysiology of HFpEF to better predict and understand responses to various treatments. Data regarding specific medications, most of them commonly used in SHF, will be reviewed. Finally, future therapies that are or will soon be tested in clinical trials will be explored.

UR - http://www.scopus.com/inward/record.url?scp=85055824949&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055824949&partnerID=8YFLogxK

M3 - Chapter

AN - SCOPUS:85055824949

SN - 9781420076998

SP - 377

EP - 387

BT - Heart Failure, Second Edition

PB - CRC Press

ER -